Neurology Minute
Dr. Derek Stitt and Dr. Jennifer Morganroth discuss why identifying carrier status is so important. Show citation: Morganroth J, Yasek J, Harms M. Preparing Amyotrophic Lateral Sclerosis Clinics to Provide Longitudinal Care for Individuals Carrying ALS Risk Variants. Neurol Genet. 2026;12(4):e200406. Published 2026 Jun 24. doi:
info_outlineNeurology Minute
Dr. Justin Abbatemarco and Sukhun Kang discuss seeding trials and other hidden marketing tactics in clinical trials, and their implications for clinical practice and patient care. Show citation: Kang S, Lin I, Ekblom M, and Chang S. Clinical trials that are actually marketing ploys targeting doctors – how seeding trials put profit over patients. The Conversation. 2026;6(5). doi:
info_outlineNeurology Minute
Dr. Margarita Fedorova discusses the DRAIN trial and the efficacy of acetazolamide in idiopathic normal pressure hydrocephalus. Show citation: Virhammar J, Fasth O, Ekblom M, et al. Safety, tolerability, and efficacy of acetazolamide in idiopathic normal pressure hydrocephalus (DRAIN) in Sweden: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2026;25(6):550-559. doi:
info_outlineNeurology Minute
Dr. Matthew Robbins discusses the assessment and diagnosis of headache in emergency settings, emphasizing red and green flags to differentiate primary from secondary headaches. This episode provides practical tips for trainees and clinicians to improve headache management. Show citation: Robbins MS. Diagnosis and Management of Headache: A Review. JAMA. 2021;325(18):1874-1885. doi:
info_outlineNeurology Minute
In the second episode of this series, Dr. Dara Albert and Dr. Scott Perry discuss common barriers to transitioning from pediatric to adult care and share practical strategies clinicians can use to support successful patient transitions. Show citation: Perry MS, Nascimento FA, Pina-Garza JE, et al. Addressing Barriers to Transitioning Pediatric Patients With Epilepsy to Adult Health Care in the United States: A Narrative Review. Neurol Clin Pract. 2026;16(3):e200616. doi:
info_outlineNeurology Minute
To celebrate 75 years of Neurology®, Dr. Chris Boes and Dr. José Merino discuss the journal’s history, its evolution, and what lies ahead for the future of Neurology®. Read more about the first .
info_outlineNeurology Minute
In part one of this series, Dr. Dara Albert and Dr. Scott Perry discuss what every neurology resident should know about caring for young adults with epilepsy as they transition from pediatric to adult neurology. Show citation: Perry MS, Nascimento FA, Pina-Garza JE, et al. Addressing Barriers to Transitioning Pediatric Patients With Epilepsy to Adult Health Care in the United States: A Narrative Review. Neurol Clin Pract. 2026;16(3):e200616. doi:
info_outlineNeurology Minute
In this episode, Dr. Jonathan Crowe reviews the Capitol Hill Report from June 22nd, discussing milestones related to the Improving Seniors' Timely Access to Care Act. Stay updated with what’s happening on the hill by visiting . Learn how you can get involved with .
info_outlineNeurology Minute
In the third part of this series, Dr. Halley Alexander explores emerging trends and recent advances in epilepsy. Show citation: Tolchin B, Goldstein LH, Reuber M, et al. Management of Functional Seizures Practice Guideline Executive Summary: Report of the AAN Guidelines Subcommittee. Neurology. 2026;106(1):e214466. doi: Hingray C, Popkirov S, Kozlowska K, et al. Functional/dissociative seizures: Proposal for a new diagnostic label and definition by the ILAE task force. Epilepsia. 2025;66(11):4162-4182. doi: Krauss GL, Elizebath R, Wheless SSJW, et al. Phase III...
info_outlineNeurology Minute
In the third part of this series, Dr. Halley Alexander explores emerging trends and recent advances in epilepsy. Show citation: Tolchin B, Goldstein LH, Reuber M, et al. Management of Functional Seizures Practice Guideline Executive Summary: Report of the AAN Guidelines Subcommittee. Neurology. 2026;106(1):e214466. doi: Hingray C, Popkirov S, Kozlowska K, et al. Functional/dissociative seizures: Proposal for a new diagnostic label and definition by the ILAE task force. Epilepsia. 2025;66(11):4162-4182. doi: Krauss GL, Elizebath R, Wheless SSJW, et al. Phase III...
info_outlineIn part one of this series, Dr. Andy Southerland and Dr. Dan Ackerman discuss what stands out in the latest thrombolysis guidelines, how these decisions are applied in stroke center practice, and how to educate residents and fellows on incorporating new evidence into treatment choices.
Show transcript:
Dr. Andy Southerland:
Hi. This is Andy Southerland from the University of Virginia, and for today's Neurology Minute, I'm speaking with my friend and colleague, Dan Ackerman, Chief of Neurology and Director of Stroke at St. Luke's University Health System. I've been speaking with Dan on the main neurology podcast regarding updates to acute stroke treatment related to the 2026 American Heart Association guidelines that came out in late January of this year on the early management of patients with acute ischemic stroke.
For our episode today, we might focus our discussion around thrombolytic therapy thrombolysis, which is at the core of what we do as acute stroke neurologists when it comes to treatment decision-making. So maybe as a first prompt, Dan, when you look at these guidelines, what stands out to you as you're thinking about how you practice, how you all are practicing at your stroke center, and then specifically how we educate our residents, our fellows on what they need to know, particularly the newness of it when it comes to making thrombolysis treatment decisions?
Dr. Dan Ackerman:
With all the discussions we've had in the past, there have been a lot of specifics about certain studies and how they might affect practice, but this guideline really opened up a lot and gave us an opportunity to do things in a way that makes really good clinical sense and really brings a lot of practices that have now become common at some centers into the fore so that we can get that information out to everyone and make sure everyone has that same really high level of stroke care everywhere they go.
I think the first thing that stands out to me is what did not change. And want to reinforce that, particularly for people who are just getting into this, stroke alert is a screening tool, not a severity score. It's not like an MI alert where you do an EKG and you see the tombstone wave and you say, "Oh, there's an MI and we're taking them to treatment." This is a screening tool, so it is meant to be highly sensitive at the cost of being specific.
At our shop for a long time now, we have initiated stroke alert for anyone who presents either within 24 hours of acute onset of neurologic symptoms or has an unknown onset of acute neurologic symptoms and they are still symptomatic to some degree at the time of their presentation, and that's it. We don't make any other statements about how severe something is or what kinds of symptoms someone necessarily has to have. We purposely keep it as broad as possible, again, because we're trying to screen.
And the other thing that has not changed, time is still brain. So with all of these different nuances on how we can treat patients and who might be candidates for intervention, it is still a matter of understanding these guidelines, applying our best evidence, but doing it as quickly as possible to make sure that we are rescuing as much of that ischemic penumbra as we possibly can.
Now, aside from that, in terms of what stands out that is different, I think one of the early things for me are the recommendations for extended time window for IV thrombolysis. So when you look at the original studies, we understand that when you get out beyond four and a half hours, if you just take all-comers, the risk is going to start to outweigh the benefit. But that doesn't mean there's zero benefit or that no one would receive benefit, but it's a question of, well, how do we cherry-pick those patients who may still receive benefit? And there are a few real specifics in the guideline that help us figure that out.
One is for patients who have an unknown time of onset, but they're within four and a half hours of symptom discovery. And for those patients, they would suggest that doing a stat MRI and comparing a DWI lesion with the corresponding area flare to determine if you see DWI hyper-intensity and the flare image is nice and normal, that would suggest that stroke is young enough that it may still be appropriate to treat that patient.
But we would also say for folks who have salvageable ischemic penumbra, so again, brain at risk that is not core yet, who either awoke with stroke symptoms within nine hours from the midpoint of sleep or, and this is the kicker, are within four and a half to nine hours from last known well. So in other words, they may have been symptomatic already for more than four and a half hours. If those patients have an appropriate ischemic penumbra, it may be reasonable to treat them with IV thrombolysis to improve functional outcomes.
Dr. Andy Southerland:
Well, that's all for this Neurology Minute. We hope this vibrant conversation will help all those who are out looking to make the best treatment decisions for their patients, both based on established evidence and most recent evidence in our new guidelines.